153 related articles for article (PubMed ID: 26406865)
21. Molecular followup of newly diagnosed bladder cancer using urine samples.
Shigyo M; Sugano K; Tobisu K; Tsukamoto T; Sekiya T; Kakizoe T
J Urol; 2001 Oct; 166(4):1280-5. PubMed ID: 11547058
[TBL] [Abstract][Full Text] [Related]
22. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
[TBL] [Abstract][Full Text] [Related]
23. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma.
Soukup V; Kalousová M; Capoun O; Sobotka R; Breyl Z; Pešl M; Zima T; Hanuš T
Urol Int; 2015; 95(1):56-64. PubMed ID: 25662337
[TBL] [Abstract][Full Text] [Related]
24. [The significance of urine cytology three consecutive days after transurethral resection as a predictor of superficial bladder cancer recurrence].
Yumura Y; Takase K; Kato Y; Hamano A; Mikata K; Ogo Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Mar; 50(3):171-6. PubMed ID: 15148768
[TBL] [Abstract][Full Text] [Related]
25. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
[TBL] [Abstract][Full Text] [Related]
26. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.
Behnsawy HM; Miyake H; Abdalla MA; Sayed MA; Ahmed Ael-F; Fujisawa M
Urol Oncol; 2011; 29(5):495-501. PubMed ID: 19914103
[TBL] [Abstract][Full Text] [Related]
27. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence.
Naselli A; Introini C; Timossi L; Spina B; Fontana V; Pezzi R; Germinale F; Bertolotto F; Puppo P
Eur Urol; 2012 May; 61(5):908-13. PubMed ID: 22280855
[TBL] [Abstract][Full Text] [Related]
28. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
29. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
30. Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors.
Foutadakis S; Avgeris M; Tokas T; Stravodimos K; Scorilas A
Urol Oncol; 2014 Jan; 32(1):39.e29-36. PubMed ID: 23790536
[TBL] [Abstract][Full Text] [Related]
31. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Barski D; Otto T; Gerullis H
Tumour Biol; 2017 May; 39(5):1010428317701624. PubMed ID: 28468590
[TBL] [Abstract][Full Text] [Related]
32. Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker.
Choi S; Shin JH; Lee YR; Joo HK; Song KH; Na YG; Chang SJ; Lim JS; Jeon BH
Dis Markers; 2016; 2016():7276502. PubMed ID: 27057081
[TBL] [Abstract][Full Text] [Related]
33. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
34. Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer.
Mutlu N; Turkeri L; Emerk K
Clin Chem Lab Med; 2003 Aug; 41(8):1069-74. PubMed ID: 12964816
[TBL] [Abstract][Full Text] [Related]
35. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer.
Mengual L; Lozano JJ; Ingelmo-Torres M; Gazquez C; Ribal MJ; Alcaraz A
Int J Cancer; 2013 Dec; 133(11):2631-41. PubMed ID: 23686449
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
[TBL] [Abstract][Full Text] [Related]
37. [Significance of random biopsies of healthy mucosa in superficial bladder tumor].
Fernández Gómez JM; Rodríguez Martínez JJ; Escaf Barmadah S; Pérez García J; García J; Casasola Chamorro J
Arch Esp Urol; 2000 Nov; 53(9):785-97. PubMed ID: 11196385
[TBL] [Abstract][Full Text] [Related]
38. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
39. A multi-analyte assay for the non-invasive detection of bladder cancer.
Goodison S; Chang M; Dai Y; Urquidi V; Rosser CJ
PLoS One; 2012; 7(10):e47469. PubMed ID: 23094052
[TBL] [Abstract][Full Text] [Related]
40. CCL18 in a multiplex urine-based assay for the detection of bladder cancer.
Urquidi V; Kim J; Chang M; Dai Y; Rosser CJ; Goodison S
PLoS One; 2012; 7(5):e37797. PubMed ID: 22629457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
